Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
The new diagnostic criteria for Alzheimer's disease (AD) include brain imaging and cerebrospinal fluid (CSF) biomarkers, with the aim of increasing the certainty of whether a patient has an ongoing AD neuropathologic process or not.
Why it matters
This review summarizes how three spinal fluid biomarkers reflect the core pathology of Alzheimer's disease and can detect it before symptoms appear. It covers diagnosis and staging and does not describe any treatment or cure.
-
Tau protein and amyloid s (Abeta), two major components of neuropathology in Alzheimer disease (AD), have been applied for establishment of more useful biomarkers and therapeutic approaches.
Why it matters
This paper discusses tau and amyloid as biomarkers and explores possible neuroprotective strategies for Alzheimer's disease, including a mechanism of amyloid toxicity involving down-regulation of XIAP. It is a broad biological discussion, not a clinical demonstration that any treatment, cure or prevention works in people.
-
Cytonectin is a novel 35,000 molecular weight protein that displays remarkable ion-independent adherence properties.
Why it matters
This paper describes the protein cytonectin and reports that it is overexpressed in the entorhinal cortex in Alzheimer disease. It is a descriptive report of a protein's presence and proposes a possible role, without testing any treatment, cure or prevention.
-
Back to table of contents Previous article Next article Clinical & Research NewsFull AccessFew Alzheimer’s Patients Get State-of-Art CareJim RosackJim RosackSearch for more papers by this authorPublished Online:20 Apr 2001https://doi.org/10.1176/pn.36.8.0042Preliminary data suggest that a huge treatment gap exists in patients with Alzheimer’s disease, with as many as 65 percent of patients with the progressive and terminal disorder going undiagnosed and, therefore, untreated.
Why it matters
Preliminary data suggested that many Alzheimer's patients go undiagnosed and untreated, partly because primary care physicians may not see value in treatment. This concerns diagnosis and care gaps, not a treatment, cure, or prevention for the disease.
-
Amyloid immunotherapy with lecanemab and donanemab has been approved on the basis of statistically significant slowing of cognitive and functional decline in early Alzheimer's disease (1,2).
Why it matters
This article argues that patients should be selected for amyloid immunotherapy based on their tau burden, since post-hoc and open-label analyses of the Clarity AD and TRAILBLAZER-ALZ 2 programmes suggest people with absent, low or medium tau may respond best. The author states these observations remain hypotheses from subgroup and open-label data, not from prospective trials designed to test them.
-
26/100
The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact.
Why it matters
This study combined deep learning with automated MRI segmentation, focusing on hippocampal extraction as a biomarker, and reported improved diagnostic capability compared with existing approaches. It is a diagnostic method study, not a treatment or cure.
-
Alzheimer disease is characterized by gradual and progressive neurodegeneration caused by neuronal cell death.
Why it matters
This review describes Alzheimer's disease as progressive neurodegeneration with loss of cholinergic neurons, and discusses hypotheses involving neurotransmitter imbalance and inflammatory mediators. It covers risk factors, biomarkers, and currently approved drugs such as cholinesterase inhibitors and memantine, along with newer anti-amyloid, anti-tau, anti-inflammatory, and neuroprotective approaches, but it reports no new treatment or cure.
-
Esse artigo buscou abordar a Doença de Alzheimer de Início Precoce (DAIP) acerca do curso clínico, dos fatores predisponentes e do manejo, por meio de uma revisão de literatura, com ênfase na diferenciação entre DAIP e Doença de Alzheimer de Início Tardio (DAIT), incluindo artigos publicados entre 2015 e 2025, obtidos nas bases de dados “Alzheimer's Association”, “ScienceDirect”, “Cochrane” e “PubMed”, utilizando as palavras-chave “Alzheimer”, “early” e “on-set”, com o conectivo AND.
Why it matters
This literature review describes that early-onset Alzheimer's disease has a more aggressive clinical course with non-amnestic manifestations, and that genetic mutations in PSEN1, PSEN2 and APP are among the predisposing factors. It discusses diagnosis and management including symptomatic control and emerging therapies, but presents no new treatment or cure.
-
Down syndrome (DS), caused by trisomy 21, is the most frequent genetic cause of intellectual disability worldwide.
Why it matters
This review discusses how nearly all adults with Down syndrome develop amyloid pathology by midlife, and that experimental and preliminary clinical evidence suggests restoring gonadotropin-releasing hormone signaling may improve cognition. This is early evidence and not yet a proven treatment.
-
Im Zuge der Alzheimerkrankheit lagern sich Beta-Amyloid-Plaques im Gehirn ab.
Why it matters
Lecanemab binds soluble beta-amyloid fibrils and promotes their clearance, but anti-amyloid therapies can cause ARIA on MRI, making regular monitoring necessary. A strong DWMH burden appears to correlate with a significantly higher ARIA risk, and larger studies are needed to identify further vascular biomarkers.
-
El objetivo de este trabajo es desarrollar un algoritmo de forrajeo de bacterias para el alineamiento múltiple de secuencias genéticas.
Why it matters
This work compares two bacterial foraging algorithms for aligning Alzheimer-related gene sequences (TREM2, EPHA1, ABCA7) and reports that bactAtp generally reached higher fitness values than bactOf. It is a computational methods study and provides no information about treating, curing or preventing Alzheimer's disease.
-
Yeni bilimsel araştırma, Alzheimer hastalığının %90’ından fazlasının APOE geniyle bağlantılı olabileceğini ortaya koydu.
Why it matters
This Turkish-language report states that new scientific research indicates more than 90% of Alzheimer disease cases may be linked to the APOE gene. It says the role of the APOE ε3 and ε4 variants in Alzheimer and dementia risk is fundamentally changing treatment and prevention strategies.
-
26/100
El Alzheimer es un trastorno neurodegenerativo que afecta la cognición y memoria.
Why it matters
This study used differential equation simulations to model galantamine, lecanemab, and non-pharmacological treatment such as physiotherapy during Alzheimer's progression. The simulated combination showed a beneficial effect on cognitive performance and biomarker accumulation, but these are computer model results, not findings from patients.
-
La enfermedad de Alzheimer (EA) es la demencia neurodgenerativa más prevalente a nivel mundial, en los últimos años se ha resaltado su relación con los trastornos del sueño y la desregulación de la melatonina.
Why it matters
This systematic review found that poor sleep quality, circadian fragmentation, and sleep breathing disorders are associated with increased Alzheimer's risk and worse clinical course, especially in women and APOE ε4 carriers. It reports that preclinical evidence supports melatonin's neuroprotective effects, with greater benefit in early stages, but states that clinical trials are needed to define causality, dose, and optimal intervention windows.
-
Introdução: Avanços recentes na pesquisa de biomarcadores e estruturas diagnósticas, como o sistema de classificação ATN, redefiniram a abordagem do diagnóstico e tratamento precoces.
Why it matters
This review reports that molecular diagnostic advances, including amyloid and tau biomarkers and the ATN framework, have improved early detection of Alzheimer's disease, and that immunotherapies such as aducanumab and lecanemab showed promise in slowing progression. It notes that accessibility and cost remain the main barriers to these emerging therapies.
-
Introdução: A doença de Alzheimer (DA) é uma condição neurodegenerativa progressiva, caracterizada pelo acúmulo de placas de β-amiloide e emaranhados neurofibrilares.
Why it matters
This review of 15 randomized trials found that BACE1 inhibitors significantly lowered beta-amyloid levels in cerebrospinal fluid and plasma, but did not slow cognitive decline, and some studies reported worsening function in treated patients. Adverse events were also reported, so these drugs are not currently an effective treatment for mild to moderate Alzheimer's disease.
-
26/100
All articles of this category (opens in new window) Die zerebrale Amyloidangiopathie (CAA) ist eine Erkrankung, bei der sich beta-Amyloid in den Gefäßwänden des Gehirns ablagert.
Why it matters
This review states that cerebral amyloid angiopathy is a major cause of lobar brain hemorrhage and dementia, and that ARIA occurs in 40% of patients on anti-amyloid immunotherapy such as aducanumab, requiring special management strategies. It describes risks and management considerations but reports no cure or prevention.
-
ResumenLa enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa crónica que se caracteriza por la acumulación excesiva de proteína beta-amiloide y de proteína Tau fosforilada.
Why it matters
This review describes how cerebrospinal fluid biomarkers (Aβ42, the Aβ42/Aβ40 ratio, t-Tau, p-Tau181) and the AT(N)I classification are used to diagnose Alzheimer's disease, with plasma p-Tau217 described as one of the most promising emerging biomarkers. It states that Alzheimer's currently has no cure, and that the FDA recently approved donanemab and lecanemab, which remove amyloid plaque and slow cognitive decline but are not free of side effects.
-
26/100
Die zerebrale Amyloidangiopathie (CAA) ist eine Erkrankung, bei der sich beta-Amyloid in den Gefäßwänden des Gehirns ablagert.
Why it matters
This review states that cerebral amyloid angiopathy is a major cause of lobar brain hemorrhage and dementia, and that ARIA occurs in 40% of patients on anti-amyloid immunotherapy such as aducanumab, requiring special management strategies. It describes risks and management considerations but reports no cure or prevention.
-
Este artículo cuestiona la dicotomía entre realismo y constructivismo en la filosofía de la ciencia, argumentando que resulta insuficiente para comprender entidades biomédicas como el Alzheimer.
Why it matters
This is a philosophical article proposing the concept of 'resfactum' to describe Alzheimer's disease as both a biological and socially shaped entity, using the PSEN1-E280A mutation as an example. It does not report any treatment, cure or prevention findings.
-
26/100
A Doença de Alzheimer (DA) é uma enfermidade neurodegenerativa progressiva cuja detecção precoce é essencial para intervenções terapêuticas eficazes.
Why it matters
This systematic review found that plasma p-Tau217 had the highest diagnostic accuracy, followed by p-Tau181 and Aβ42/Aβ40, and concluded that combining markers may improve early diagnosis. It is about diagnosis, not treatment, and does not demonstrate any cure or prevention.
-
Penyakit Alzheimer adalah jenis demensia akibat kerusakan pada neuron otak yang memengaruhi memori, bahasa, dan berpikir.
Why it matters
Three 3D CNN architectures classified Alzheimer's dementia severity on ADNI MRI scans, with 3D ResNet reaching 99.54% training accuracy and 3D CNN + CLSTM reaching 100% test accuracy. This is a comparison of classification models, not a treatment, cure, or prevention.
-
To investigate the effect and mechanism of etomidate on attenuating Alzheimer-like neuropathology and cognitive impairment in mice with Alzheimer's disease (AD).
Why it matters
In APP/PS1 mice and in hippocampal neuron cells, etomidate improved memory and spatial learning and reduced amyloid-beta deposition, neuron and synaptic loss, and regulated neuroinflammation and neurotransmitters. This is an animal and cell study, so it does not establish that etomidate treats Alzheimer's disease in people.
-
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment.
Why it matters
Kisunla (donanemab-azbt) is described as a disease-modifying treatment for people with early-stage Alzheimer disease with confirmed amyloid pathology, and nearly half of research participants finished treatment within a year. The text claims extremely significant results but provides no specific outcome data.
-
Eine von 5 Frauen und einer von 10 Männern entwickeln eine Demenz vom Alzheimer-Typ, erläutern Palmqvist et al. zu Beginn ihrer Studie [1].
Why it matters
A Swedish group presents a blood test combining percentage phosphorylated tau217 and the Aβ42/Aβ40 ratio (APS2) for Alzheimer's disease. This is a diagnostic approach; the text does not report any treatment, cure, or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Plasma proteomic profiles predict future dementia in healthy adults
- Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease
- Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages
- The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease
- Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy
- Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease
- Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
- EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease
- Magnetic Resonance Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in Alzheimer Disease
- Structural progression of Alzheimer's disease over decades: the MRI staging scheme